CBAY News and Press, CymaBay Therapeutics Inc. From 04/21/21

Gainers: [[XM]] +7.9%. [[CHDN]] +6.0%. [[IRDM]] +4.8%. [[UFPI]] +4.8%. [[SYBX]] +4.4%.Losers: [[EOLS]] -13.7%. [[AZN]] -7.9%. [[CBAY]] -6.6%. [[SNBR]] -6.0%. [[CENX]] -5.7%. For further details see: XM, IRDM, EOLS and AZN among after-hours movers

Gainers: [[GLYC]] +3.5%. [[CBAY]] +2.6%. [[KPTI]] +2.6%. [[GMAB]] +2.5%. [[SYRS]] +2.4%.Losers: [[VECT]] -8.1%. [[TCRR]] -2.4%. [[JFIN]] -2.3%. [[CENX]] -2.2%. [[GURE]] -1.8%. For further details see: KPTI, CENX, GMAB and TCRR among after-hours movers

NEWARK, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of biopharma veteran Thomas Wig...

Image source: The Motley Fool. CymaBay Therapeutics Inc. (NASDAQ: CBAY) Q4 2020 Earnings Call Mar 25, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: CymaBay Therapeutics Inc. (CBAY) Q4 2020 Earnings Call Transcript...

Cymabay Therapeutics, Inc. (CBAY) Q4 2020 Earnings Conference Call March 25, 2021, 16:30 ET Company Participants Daniel Menold - VP, Finance Sujal Shah - President, CEO & Director Charles McWherter - SVP & Chief Scientific Officer Klara Dickinson - Chief Regulatory & Quality Assur...

CymaBay Therapeutics (CBAY): Q4 GAAP EPS of -$0.23 misses by $0.03.Held $146.3 million in cash, cash equivalents and short-term investments on December 31, 2020. We believe that cash and investments are sufficient to fund CymaBay’s current operating plan into mid-2022.Shares -0.44%.Pre...

Actively recruiting patients in two global, clinical studies evaluating seladelpar in primary biliary cholangitis (PBC): RESPONSE, a 52-week, randomized, placebo-controlled, Phase 3 registrational study ASSURE, an open-label, long-term study Two pipeline prog...

NEWARK, Calif., March 12, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live au...

NEWARK, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that two seladelpar presentations will be deliv...

Today, we are posting a deep dive on CymaBay Therapeutics, one of the most volatile small-cap biotech names in the market. CymaBay's main drug candidate looks on its way to garnering FDA approval for primary biliary cholangitis. An analysis on CymaBay and what might be ahead for t...